158 related articles for article (PubMed ID: 38436810)
21. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258
[TBL] [Abstract][Full Text] [Related]
22. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo.
Chen J; Jin S; Abraham V; Huang X; Liu B; Mitten MJ; Nimmer P; Lin X; Smith M; Shen Y; Shoemaker AR; Tahir SK; Zhang H; Ackler SL; Rosenberg SH; Maecker H; Sampath D; Leverson JD; Tse C; Elmore SW
Mol Cancer Ther; 2011 Dec; 10(12):2340-9. PubMed ID: 21914853
[TBL] [Abstract][Full Text] [Related]
23. Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.
Ren W; Joshi R; Mathew P
Mol Cancer Res; 2016 Dec; 14(12):1176-1181. PubMed ID: 27590631
[TBL] [Abstract][Full Text] [Related]
24. Phase IB Study of Osimertinib in Combination with Navitoclax in
Bertino EM; Gentzler RD; Clifford S; Kolesar J; Muzikansky A; Haura EB; Piotrowska Z; Camidge DR; Stinchcombe TE; Hann C; Malhotra J; Villaruz LC; Paweletz CP; Lau CL; Sholl L; Takebe N; Moscow JA; Shapiro GI; Jänne PA; Oxnard GR
Clin Cancer Res; 2021 Mar; 27(6):1604-1611. PubMed ID: 33376097
[TBL] [Abstract][Full Text] [Related]
25. Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models.
Tan N; Malek M; Zha J; Yue P; Kassees R; Berry L; Fairbrother WJ; Sampath D; Belmont LD
Clin Cancer Res; 2011 Mar; 17(6):1394-404. PubMed ID: 21220478
[TBL] [Abstract][Full Text] [Related]
26. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax.
Kour S; Rana S; Contreras JI; King HM; Robb CM; Sonawane YA; Bendjennat M; Crawford AJ; Barger CJ; Kizhake S; Luo X; Hollingsworth MA; Natarajan A
Mol Pharmacol; 2019 Oct; 96(4):419-429. PubMed ID: 31467029
[TBL] [Abstract][Full Text] [Related]
27. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wilson WH; O'Connor OA; Czuczman MS; LaCasce AS; Gerecitano JF; Leonard JP; Tulpule A; Dunleavy K; Xiong H; Chiu YL; Cui Y; Busman T; Elmore SW; Rosenberg SH; Krivoshik AP; Enschede SH; Humerickhouse RA
Lancet Oncol; 2010 Dec; 11(12):1149-59. PubMed ID: 21094089
[TBL] [Abstract][Full Text] [Related]
28. The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.
Matzinger O; Viertl D; Tsoutsou P; Kadi L; Rigotti S; Zanna C; Wiedemann N; Vozenin MC; Vuagniaux G; Bourhis J
Radiother Oncol; 2015 Sep; 116(3):495-503. PubMed ID: 26096848
[TBL] [Abstract][Full Text] [Related]
29. A novel Bcl-2 inhibitor, BM-1197, induces apoptosis in malignant lymphoma cells through the endogenous apoptotic pathway.
Sun YL; Jiang WQ; Luo QY; Yang DJ; Cai YC; Huang HQ; Sun J
BMC Cancer; 2019 Dec; 20(1):1. PubMed ID: 31892356
[TBL] [Abstract][Full Text] [Related]
30. Naringenin-Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways.
Lim W; Park S; Bazer FW; Song G
J Cell Biochem; 2017 May; 118(5):1118-1131. PubMed ID: 27606834
[TBL] [Abstract][Full Text] [Related]
31. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
Li L; Zhu Z; Joshi B; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
[TBL] [Abstract][Full Text] [Related]
32. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and Phospho-BAD.
Pareja F; Macleod D; Shu C; Crary JF; Canoll PD; Ross AH; Siegelin MD
Mol Cancer Res; 2014 Jul; 12(7):987-1001. PubMed ID: 24757258
[TBL] [Abstract][Full Text] [Related]
33. Optimizing combination therapy in prostate cancer: mechanistic insights into the synergistic effects of Paclitaxel and Sulforaphane-induced apoptosis.
Habib TN; Altonsy MO; Ghanem SA; Salama MS; Hosny MA
BMC Mol Cell Biol; 2024 Mar; 25(1):5. PubMed ID: 38438917
[TBL] [Abstract][Full Text] [Related]
34. Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models.
Tan N; Wong M; Nannini MA; Hong R; Lee LB; Price S; Williams K; Savy PP; Yue P; Sampath D; Settleman J; Fairbrother WJ; Belmont LD
Mol Cancer Ther; 2013 Jun; 12(6):853-64. PubMed ID: 23475955
[TBL] [Abstract][Full Text] [Related]
35. Navitoclax combined with Alpelisib effectively inhibits Merkel cell carcinoma cell growth
Chteinberg E; Wetzels S; Gerritsen W; Temmerman L; van den Oord J; Biessen E; Kurz AK; Winnepenninckx V; Zenke M; Speel EJ; Zur Hausen A
Ther Adv Med Oncol; 2020; 12():1758835920975621. PubMed ID: 33403016
[TBL] [Abstract][Full Text] [Related]
36. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
[TBL] [Abstract][Full Text] [Related]
37. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
[TBL] [Abstract][Full Text] [Related]
38. The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells.
Ye L; Yuan G; Xu F; Sun Y; Chen Z; Chen M; Li T; Sun P; Li S; Sun J
Tumour Biol; 2015 May; 36(5):3447-55. PubMed ID: 25542230
[TBL] [Abstract][Full Text] [Related]
39. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
[TBL] [Abstract][Full Text] [Related]
40. Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer.
Lopez A; Reyna DE; Gitego N; Kopp F; Zhou H; Miranda-Roman MA; Nordstrøm LU; Narayanagari SR; Chi P; Vilar E; Tsirigos A; Gavathiotis E
Nat Commun; 2022 Mar; 13(1):1199. PubMed ID: 35256598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
